# Longevity SaaS Plan

## Market Opportunity

**Target Market:** Biohackers, longevity enthusiasts, longevity clinics
**Market Size:** Growing rapidly (Bryan Johnson, Huberman, Attia followers)
**Competitors:** InsideTracker ($589/yr), Function Health ($499/yr), Viome ($400+)
**Our Edge:** Graph-based personalized discovery vs static reports

## Revenue Model

### Pricing Tiers

**Premium - $99/month**
- Genetics upload (23andMe, WGS VCF)
- Pathway analysis (22 longevity pathways)
- Personalized treatment/supplement recommendations
- Biomarker tracking dashboard

**Pro - $199/month**
- Advanced graph-based discovery queries
- Peptide therapy recommendations
- Wearable/lab integration
- Practitioner consultation access

**Enterprise - $999+/month**
- White-label for longevity clinics
- Multi-patient management
- Custom pathway models
- API access

**Revenue Projection:**
- Conservative: 1,000 users × $99 = $1.2M ARR
- Aggressive: 10,000 users × $149 = $17.9M ARR

## Technical Implementation

### Current Assets (80% Complete)
- ✅ Gene, protein, pathway database
- ✅ Treatment, biomarker, enhancement tracking
- ✅ Graph database (Kuzu) for relationship discovery
- ✅ Disease associations
- ✅ Peptide database

### Required Additions

**1. Longevity Pathway Mapping**
- Map 22 pathways to existing gene entities
- Create pathway tier classification (S/A/B/C/D)
- Link treatments/supplements to pathway targets

**2. Genetics Processing**
- Upload handler for 23andMe raw data, VCF files
- Variant annotation pipeline
- Pathway impact scoring algorithm

**3. Recommendation Engine**
Graph queries like:
```cypher
MATCH (u:User)-[:HAS_VARIANT]->(v:Variant)-[:LOCATED_IN]->(g:Gene)
MATCH (g)-[:PART_OF]->(pw:Pathway {tier: 'S'})
MATCH (t:Treatment)-[:ENHANCES]->(g)
WHERE v.impact = 'negative'
RETURN t, g, pw, evidence_strength
ORDER BY pw.tier, evidence_strength DESC
```

**4. Biomarker Tracking**
- Time-series storage for user biomarkers
- Pathway health scores over time
- Intervention efficacy tracking

## Core Recommendations

### 1. Supplements/Nutraceuticals
- NMN/NR (NAD+ pathway)
- Metformin/Berberine (AMPK)
- Resveratrol (sirtuins)
- Rapamycin analogs (mTOR)

### 2. Peptides
- Epithalon (telomeres)
- MOTS-c (mitochondria)
- GHK-Cu (tissue repair)
- Thymosin Beta-4 (inflammation)

### 3. Lifestyle Interventions
- Fasting protocols (insulin/IGF-1 genes)
- Exercise plans (AMPK/mitochondrial variants)
- Sleep optimization (circadian genes)

### 4. Biomarker Monitoring
- HbA1c, fasting insulin (Tier S)
- NAD+/NADH ratio (Tier S)
- hs-CRP, IL-6 (Tier A)
- Homocysteine (Tier C)

### 5. Advanced Therapies
- Senolytics (cellular senescence)
- NAD+ IV therapy
- Hyperbaric oxygen
- Stem cell therapies

## Differentiation

**Generic platforms:** "Take these 50 longevity supplements"

**Our platform:** "Your NMNAT1 variant reduces NAD+ synthesis. Prioritize NMN 500mg over NR based on your genetics. Track NAD+/NADH ratio monthly."

**Key value:** Precision longevity via graph-based pathway analysis

## MVP Strategy

### Phase 1: Core Validation (Month 1-2)
1. Focus on Tier S pathways (4 pathways = 60% impact)
   - Insulin/IGF-1
   - mTOR
   - AMPK
   - Sirtuins
2. Build genetics upload + variant annotation
3. Create pathway scoring algorithm
4. Treatment recommendations from existing DB
5. Launch at $49/month beta pricing

### Phase 2: User Acquisition (Month 3-4)
1. Validate with 10-100 beta users
2. Content marketing (SEO: longevity keywords)
3. Partnerships with biohacker influencers
4. Iterate based on feedback

### Phase 3: Scale (Month 5-6)
1. Add Tier A pathways
2. Biomarker tracking dashboard
3. Increase pricing to $99/month
4. B2B outreach to longevity clinics

## Risks & Mitigation

### Regulatory
- **Risk:** Health claims regulation
- **Mitigation:** Wellness insights (not medical diagnosis), disclaimers, health law attorney review

### Data Quality
- **Risk:** Longevity science evolving rapidly
- **Mitigation:** Peer-reviewed source citations, continuous curation, research partnerships

### Competition
- **Risk:** Market heating up fast
- **Mitigation:** Graph DB moat, first-mover on personalized discovery

### Privacy/Security
- **Risk:** HIPAA compliance for genetic data
- **Mitigation:** Encrypted storage, SOC2 compliance, user data controls

## Success Metrics

**Month 1-3:**
- 10 beta users paying $49/month
- 90%+ user satisfaction
- 5+ case studies with measurable biomarker improvements

**Month 4-6:**
- 100 users paying $99/month = $10k MRR
- 1 longevity clinic white-label deal
- <5% monthly churn

**Year 1:**
- 1,000 users = $100k MRR = $1.2M ARR
- 10 clinic partnerships
- Break-even on ops costs

## Commercial Viability: 7/10

**Pros:**
- Proven market demand
- 80% tech infrastructure ready
- Unique graph-based differentiation
- High margins (SaaS)

**Cons:**
- Regulatory complexity
- Requires ongoing scientific curation
- User acquisition in niche market
- HIPAA compliance costs
